Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.

An open-label, long-term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL-M/CLD 20/12.5mg (n=77) or OLM/HCTZ 20/12.5mg (n=76), but could be up-titrated (AZL-M/CLD to 40/25mg; OLM/HCTZ to 40/25mg [US] or 20/25mg [Europe]) with other agents added during weeks 4-52. Primary endpoint was proportion of participants with 1 adverse event (AE) through week 52. Baseline demographics were similar. AEs did not differ between groups (88.3%, AZL-M/CLD vs 76.3%, OLM/HCTZ; P=.058). AZL-M/CLD showed greater systolic BP reductions after initial dosing (P=.037) but not during long-term follow-up (P=.588). A greater proportion of participants up-titrated to the highest dose with OLM/HCTZ (48.7%) vs AZL-M/CLD (29.9%) (P=.021) and were taking additional antihypertensive medications (26.3% vs 16.9%). Both AZL-M/CLD and OLM/HCTZ showed similar efficacy and tolerability.